Soleno Therapeutics (SLNO) Stock; Surges 32% After Neurocrine’s $2.9B Acquisition Bid

TLDRs;

• Soleno shares surged 32% after Neurocrine announced a $2.9 billion all-cash acquisition offer.
• The $53 per share bid values Soleno near market close, reflecting strong deal approval expectations.
• Vykat XR, a rare-disease drug for Prader-Willi syndrome, is the key asset driving acquisition interest.
• Analysts see the deal strengthening Neurocrine’s rare-disease pipeline with potential billion-dollar sales upside.

Soleno Therapeutics Inc. (NASDAQ: SLNO) saw its shares skyrocket 32% following news that Neurocrine Biosciences has agreed to acquire the rare-disease biotech company in a $2.9 billion all-cash transaction. The offer, priced at $53 per share, immediately pushed Soleno’s stock close to the deal value, reflecting strong investor confidence that the transaction is likely to close without major hurdles.

By the close of trading, Soleno shares were hovering just below the bid price, signaling that the market is largely pricing in deal completion. The acquisition marks one of the most significant biotech transactions of the year, reinforcing continued consolidation in the rare-disease pharmaceutical space.

Vykat XR Drives Strategic Interest

At the center of the deal is Vykat XR, Soleno’s recently commercialized therapy for Prader-Willi syndrome, a rare genetic disorder that causes uncontrolled hunger, known medically as hyperphagia.

Vykat XR is currently the only FDA-approved treatment in the United States specifically targeting this condition. That exclusivity makes it a highly valuable asset for Neurocrine Biosciences, which is looking to strengthen its rare-disease pipeline and diversify its revenue base beyond its existing blockbuster therapies.

Soleno Therapeutics, Inc., SLNO

The drug has already begun generating traction in the market, contributing approximately $190 million in revenue during 2025, just months after its commercial rollout following FDA approval in March 2025.

Neurocrine Expands Rare-Disease Portfolio

Neurocrine Biosciences is no stranger to commercial success, with its existing portfolio including Ingrezza and Crenessity, which generated $2.51 billion and $301 million in revenue respectively in 2025. The addition of Vykat XR gives the company a third commercial rare-disease product, strengthening its long-term growth outlook.

Company leadership has described the acquisition as a strategic expansion into underserved genetic conditions, positioning Vykat XR as a “potential blockbuster in the making.” Analysts also view the move as a strong pipeline diversification play, particularly as Neurocrine leans further into specialty pharmaceuticals.

The acquisition is expected to be financed through existing cash resources and a portion of prepayable debt, with no financing contingencies attached to the deal.

Investor Optimism and Market Outlook

Market analysts reacted positively to the announcement, suggesting that Neurocrine’s acquisition strategy could significantly enhance its revenue trajectory over the next decade. Some projections estimate Vykat XR could exceed $1 billion in annual sales by 2029 if adoption trends continue.

The $53 per share offer represents a premium of more than 30% compared to Soleno’s recent trading levels prior to the announcement, further reinforcing investor enthusiasm. However, the transaction still requires regulatory approval under U.S. antitrust rules and majority shareholder acceptance before it can officially close.

Despite these conditions, both companies have expressed confidence in completing the deal within a 90-day timeline. If successful, it would mark a transformative exit for Soleno and a major expansion step for Neurocrine’s rare-disease franchise.

Prader-Willi Market Opportunity Expands

Beyond financial metrics, the acquisition highlights the growing commercial interest in rare genetic disorders with limited treatment options. With an estimated 10,000 patients in the United States suffering from Prader-Willi syndrome, Neurocrine is positioning itself in a niche but high-value therapeutic market.

For Soleno shareholders, the surge in stock price reflects both immediate takeover value and broader optimism about the drug’s long-term potential under a larger pharmaceutical umbrella. For Neurocrine, the deal signals a long-term bet on specialty therapeutics where pricing power and exclusivity remain strong drivers of profitability.

The post Soleno Therapeutics (SLNO) Stock; Surges 32% After Neurocrine’s $2.9B Acquisition Bid appeared first on CoinCentral.